News & Updates

Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022

In patients with high-risk or unfavourable nonmetastatic prostate cancer (nmPC) receiving local definite therapy, the intensification of systemic therapy using chemotherapy or an androgen receptor signaling inhibitor (ARSI), in combination with androgen deprivation therapy (ADT), leads to better oncologic survival measures, reports a recent meta-analysis.

Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022
Intensive urate lowering of little benefit to patients with erosive gout
Intensive urate lowering of little benefit to patients with erosive gout
27 Apr 2022
Asivatrep cream safe, effective for atopic dermatitis
Asivatrep cream safe, effective for atopic dermatitis
26 Apr 2022
Novel drug promising for paediatric Tourette syndrome
Novel drug promising for paediatric Tourette syndrome
26 Apr 2022 byJairia Dela Cruz

The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).

Novel drug promising for paediatric Tourette syndrome
26 Apr 2022